Article Text

Download PDFPDF
Kaplan–Meier failure estimate for metachronous colorectal cancer risk is clinically relevant
  1. Mark A Jenkins1,
  2. Lyle C Gurrin1,
  3. Susan Parry2,3,
  4. Aung Ko Win1
  1. 1Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of Melbourne, Parkville, Victoria, Australia
  2. 2New Zealand Familial Gastrointestinal Cancer Registry, Auckland City Hospital, Auckland, New Zealand
  3. 3Department of Gastroenterology, Middlemore Hospital, Auckland, New Zealand
  1. Correspondence to Dr Mark A Jenkins, Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Population Health, Level 3, 207 Bouverie Street, The University of Melbourne, VIC 3010, Australia; m.jenkins{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Renehan1 argues that we inappropriately used the Kaplan–Meier method to estimate the risk of metachronous colorectal cancer, and instead recommends a competing risk analysis.2 While we agree that a competing risk analysis is a valid technique, we claim that the Kaplan–Meier estimate is also valid, and in this setting more appropriate.

We have reported the cumulative risk of metachronous colorectal cancer following segmental surgery for a first colon cancer for carriers of mutations in mismatch repair genes.3 Using …

View Full Text


  • Competing interests None.

  • Provenance and peer review Not commissioned; internally peer reviewed.